Calidi Biotherapeutics

CLDI

Market cap $1.92M

CLDI Hedge Fund Activity: Q1 2026 in Review

28 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q1 2026, worth a combined $479K — down 8.7% from $525K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new CLDI positions and 5 closed out — a net gain of 2 holders — while 7 added to existing stakes and 3 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $660K. The largest seller was DRW Securities, exiting entirely with an estimated $173K sold.

• 28 institutional investors held Calidi Biotherapeutics (CLDI) as of Q1 2026, up from 27 in Q4 2025.
• Funds reported $479K of Calidi Biotherapeutics stock for Q1 2026, down 8.7% quarter-over-quarter.
• 7 funds opened new Calidi Biotherapeutics positions in Q1 2026 and 5 closed out, a net change of +2 holders.
• The largest Calidi Biotherapeutics buyer in Q1 2026 was Armistice Capital, an estimated $660K added.
• The largest Calidi Biotherapeutics seller in Q1 2026 was DRW Securities, an estimated $173K sold.

Based on aggregated 13F filings for Q1 2026.